Y-mAbs Therapeutics, Inc. announced the presentation of preclinical and translational pharmacokinetics (PK) data for their CD38-SADA bispecific fusion protein at the 2025 AACR Annual Meeting in ...

Y-mAbs Therapeutics (YMAB) announced the presentation of preclinical and translational pharmacokinetics, PK, data of CD38-SADA in a poster at ...

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics ... facilitated the clinical development of other bispecific fusion proteins, including GD2-SADA, now in clinical development ...

Y-mAbs announces first patient dosed in Phase ... CD38-SADA is based on a bispecific fusion protein technology developed for targeted radioimmunotherapy. Disclaimer: This is an AI-generated ...

NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics ... the self-assembling and disassembling (SADA) bispecific fusion protein CD38-SADA for first-in-human (FIH) pretargeted ...

IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 ...

SAN FRANCISCO and SUZHOU, China, April 28, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

We engineered a novel PD1-IFNα fusion protein that combines attenuated IFNα ... superior anti-tumor efficacy compared to PD1 mAb alone in multiple mouse syngeneic tumor models, with undetectable ...

Henlius (2696) held its 2025 Global R&D Day under the theme of "Collaborate to Create". Senior executives from Henlius gathered with leading experts, scholars, and heads of innovation from across the ...

Antibody: Complex protein-based molecules ... murine hybridomas generated from the fusion of mouse myeloma and mouse B-lymphocyte cells. Chimeric mAb: A mAb constructed from variable regions ...